文献速递甲状腺疾病

激光消融与射频消融治疗甲状腺结节的随机试验:LARA II研究12个月结果

Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules: 12-Month Results of a Randomized Trial (LARA II Study).
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

两组压迫和美容评分均较基线显著改善且组间无差异。

要点

  • 两种消融技术成功率(结节缩小>50%比例)无显著组间差异。
  • RFA与LA均显著改善压迫和美容评分,组间无差异。

核心结论

  • RFA在12个月时实现显著更大的结节体积缩小,但技术成功率与LA相似。

研究设计与样本

  • 单中心、12个月、随机、优效性、开放标签、平行组试验,在门诊进行。
  • 60例孤立性或主导性良性非功能性甲状腺结节伴压迫症状/美容问题的患者按1:1随机接受单次RFA或LA。

主要发现

  • 12个月技术成功率组间无显著差异。

关键数值与推荐

  • 主要结局指标为体积缩小率(VRR)和结节缩小>50%的比例(技术成功率)。
  • 入组标准:孤立性良性非功能性甲状腺结节或主导结节,伴压迫症状/美容问题,实性或 predominantly 实性。

临床怎么用

  • 对于有压迫症状或美容问题的良性非功能性甲状腺结节,RFA和LA均可作为单次消融选项。
  • 若以更大体积缩小为目标,RFA在12个月时显示优于LA。
  • 两种技术均能显著改善压迫和美容评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Radiofrequency ablation (RFA) seems to achieve a significantly larger nodule volume reduction rate (VRR) than laser ablation (LA) in benign nonfunctioning thyroid nodules (BNTNs). OBJECTIVE: To compare the efficacy and safety of both treatments at 12-month follow-up in patients with solid or predominantly solid BNTN. METHODS: This was a single-center, 12-month, randomized, superiority, open-label, parallel-group trial conducted in an outpatient clinic. Sixty patients with a solitary BNTN or dominant nodule characterized by pressure symptoms/cosmetic problems were randomly assigned (1:1 ratio) to receive either a single session of RFA or LA. Twenty-9 patients per group completed the study. The main outcome measures were VRR and proportion of nodules with more than 50% reduction (technical success rate). RESULTS: At 12 months, VRR was 70.9 ± 16.9% and 60.0 ± 19.0% in the RFA and LA groups, respectively (P = .024). This effect was confirmed in the linear regression model that was adjusted for age, sex, nodule baseline volume, and proportion of cellular components (RFA treatment: β = .390; P = .009). No significant between-group difference was observed in the technical success rate at 12 months after treatment. A statistically significant improvement was observed from the baseline to the 12-month follow-up for compression (RFA: 4.6 ± 2.6 and 1.3 ± 0.8, P < .001; and LA: 4.6 ± 2.1 and 1.6 ± 0.8, respectively, P < .001) and cosmetic (RFA: 3.4 ± 0.6 and 1.3 ± 0.5, P < .001; and LA: 3.4 ± 0.5 and 1.4 ± 0.6, P < .001) scores although the between-group differences were not significant. CONCLUSION: RFA achieved a significantly larger nodule volume reduction at 12 months; however, the technical success rate was similar in the RFA and LA groups.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cesareo R, Manfrini S, Pasqualini V, et al. Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules: 12-Month Results of a Randomized Trial (LARA II Study). J Clin Endocrinol Metab. 2021. PMID: 33608728. doi:10.1210/clinem/dgab102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。